Antibiotic use and population ecology: How you can reduce your "resistance footprint"

CMAJ. Canadian Medical Association Journal

Volumn 180, Issue 4, 2009, Pages 416-421

  Patrick, David M ^a,c   Hutchinson, James ^b  

^a BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN; CIPROFLOXACIN; COTRIMOXAZOLE; ERYTHROMYCIN; MACROLIDE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTERIAL COLONIZATION; BRONCHITIS; CELLULITIS; DRUG HALF LIFE; ERADICATION THERAPY; ESCHERICHIA COLI; HUMAN; INFECTION; OTITIS MEDIA; PHARYNGITIS; PNEUMONIA; PRESCRIPTION; PYELONEPHRITIS; REVIEW; SINUSITIS; STREPTOCOCCUS PNEUMONIAE;

EID: 61449164000     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.080626     Document Type: Article

References (54)

1. Hoban DJ. Antibiotics and collateral damage. Clin Cornerstone 2003;Suppl 3:S12-20.
2. Baldo BA, Zhao Z, Pham NH. Antibiotic allergy: immunochemical and clinical considerations. Curr Allergy Asthma Rep 2008;8:49-55.
3. Hardin G. The tragedy of the commons. Science 1968;162:1243-8.
4. Dawkins R. Climbing mount improbable. New York (NY): Norton; 1996.
5. de la Cruz F, Davies J. Horizontal gene transfer and the origin of species: lessons from bacteria. Trends Microbiol 2000;8:128-33.
6. Rowe-Magnus DA, Guerout AM, Ploncard P, et al. The evolutionary history of chromosomal super-integrons provides an ancestry for multiresistant integrons. Proc Natl Acad Sci USA 2001;98:652-7.
7. Woodford N, Ellington MJ. The emergence of antibiotic resistance by mutation. Clin Microbiol Infect2007;13:5-18.
8. Tenover FC. Development and spread of bacterial resistance to antimicrobial agents: an overview. Clin Infect Dis2001;Suppl 3:S108-15.
9. Droge M, Puhler A, Selbitschka W. Horizontal gene transfer as a biosafety issue: a natural phenomenon of public concern. J Biotechnol 1998;64:75-90.
10. Hutchinson JM, Patrick DM, Marra F, et al. Measurement of antibiotic consumption: A practical guide to the use of the Anatomical Therapeutic Chemical classification and Defined Daily Dose system methodology in Canada. Can J Infect Dis 2004;15:29-35.
11. Patrick DM, Marra F, Hutchinson J, et al. Per capita antibiotic consumption: How does a North American jurisdiction compare with Europe? Clin Infect Dis 2004;39:11-7.
12. Bronzwaer SL, Cars O, Buchholz U, et al. A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerg Infect Dis 2002;8:278-82.
13. Goossens H, Ferech M, Vander SR, et al. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005;365:579-87.
14. Van Eldere J, Mera RM, Miller LA, et al. Risk factors for development of multiple-class resistance to Streptococcus pneumoniae strains in Belgium over a 10-year period: antimicrobial consumption, population density, and geographic location. Antimicrob Agents Chemother2007;51:3491-7.
15. Arason VA, Kristinsson KG, Sigurdsson JA, et al. Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross-sectional prevalence study. BMJ1996;313:387-91.
16. Mera RM, Miller LA, White A. Antibacterial use and Streptococcus pneumoniae penicillin resistance: A temporal relationship model. Microb Drug Resist 2006;12:158-63.
17. Livermore DM, Reynolds R, Stephens P, et al. Trends in penicillin and macrolide resistance among pneumococci in the UK and the Republic of Ireland in relation to antibiotic sales to pharmacies and dispensing doctors. Int J Antimicrob Agents 2006;28:273-9. Epub 2006 Sep 14.
18. Arason VA, Sigurdsson JA, Erlendsdottir H, et al. The role of antimicrobial use in the epidemiology of resistant pneumococci: A 10-year follow up. Microb Drug Resist 2006;12:169-76.
19. Gobernado M, Valdes L, Alos JI, et al. Antimicrobial susceptibility of clinical Escherichia coli isolates from uncomplicated cystitis in women over a 1-year period in Spain. Rev Esp Quimioter 2007;20:68-76.
20. MacDougall C, Powell JP, Johnson CK, et al. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis2005;41:435- 40.
21. Vanderkooi OG, Low DE, Green K, et al. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis2005;40:1288-97.
22. Malhotra-Kumar S, Lammens C, Coenen S, et al. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet 2007;369:482-90.
23. Dagan R, Barkai G, Leibovitz E, et al. Will reduction of antibiotic use reduce antibiotic resistance? The pneumococcus paradigm. Pediatr Infect Dis J 2006;25:981-6.
24. Girard AE, Girard D, English AR, et al. Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excel lent tissue distribution. Antimicrob Agents Chemother1987;31:1948-54.
25. Molstad S, Erntell M, Hanberger H, et al. Sustained reduction of antibiotic use and low bacterial resistance: 10-year follow-up of the Swedish Strama programme. Lancet Infect Dis2008;8:125-32.
26. HILL AB. The environment and disease: Association or causation? Proc R Soc Med1965;58:295-300.
27. Gould IM. Antibiotic policies to control hospital-acquired infection. J Antimicrob Chemother2008;61:763-5.
28. Fishman N. Antimicrobial stewardship. Am J Med2006;119(6 Suppl 1):S53-61.
29. Owens RC Jr, Rice L. Hospital-based strategies for combating resistance. Clin Infect Dis2006;42 Suppl 4:S173-81.
30. Lipsitch M, Samore MH. Antimicrobial use and antimicrobial resistance: a population perspective. Emerg Infect Dis 2002;8:347-54.
31. Bruinsma N, Hutchinson JM, van den Bogaard AE, et al. Influence of population density on antibiotic resistance. J Antimicrob Chemother2003;51:385-90.
32. Boucher HW, Corey GR. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008;Suppl 5:S344-9.
33. McEwen SA. Antibiotic use in animal agriculture: What have we learned and where are we going? Anim Biotechnol 2006;17:239-50.
34. White DG, Zhao S, Sudler R, et al. The isolation of antibiotic-resistant salmonella from retail ground meats. N Engl J Med2001;345:1147-54.
35. Marra F, Patrick DM, Chong M, et al. Antibiotic use among children in British Columbia, Canada. J Antimicrob Chemother 2006;58:830-9.
36. Ben David D, Rubinstein E. Appropriate use of antibiotics for respiratory infections: review of recent statements and position papers. Curr Opin Infect Dis 2002;15:151-6.
37. Little P, Gould C, Williamson I, et al. Pragmatic randomised controlled trial of two prescribing strategies for childhood acute otitis media. BMJ 2001;322:336-42.
38. Spurling GK, Del Mar CB, Dooley L, et al. Delayed antibiotics for respiratory infections. Cochrane Database Syst Rev 2007;(4):CD004417.
39. Nicolle L, Anderson PA, Conly J, et al. Uncomplicated urinary tract infection in women. Current practice and the effect of antibiotic resistance on empiric treatment. Can Fam Physician 2006;52:612-8.
40. Conly J. Antimicrobial resistance in Canada. CMAJ2002;167:885-91.
41. Smucny J, Fahey T, Becker L, et al. Antibiotics for acute bronchitis. Cochrane Database Syst Rev 2004:(4);CD000245.
42. Cohen R. Approaches to reduce antibiotic resistance in the community. Pediatr Infect Dis J2006;25:977-80.
43. Arroll B, Goodyear-Smith F, Thomas DR, et al. Delayed antibiotic prescriptions: What are the experiences and attitudes of physicians and patients? J Fam Pract 2002;51:954-9.
44. Mamdani M, McNeely D, Evans G, et al. Impact of a fluoroquinolone restriction policy in an elderly population. Am J Med 2007;120:893-900.
45. Parsons S, Morrow S, Underwood M. Did local enhancement of a national campaign to reduce high antibiotic prescribing affect public attitudes and prescribing rates? Eur J Gen Pract 2004;10:18-23.
46. Rubin MA, Bateman K, Alder S, et al. A multifaceted intervention to improve antimicrobial prescribing for upper respiratory tract infections in a small rural community. Clin Infect Dis2005;40:546-53.
47. Guillemot D, Varon E, Bernede C, et al. Reduction of antibiotic use in the community reduces the rate of colonization with penicillin G-nonsusceptible Streptococcus pneumoniae. Clin Infect Dis2005;41:930-8. Epub 2005 Aug 29
48. Finkelstein JA, Huang SS, Kleinman K, et al. Impact of a 16-community trial to promote judicious antibiotic use in Massachusetts. Pediatrics2008;121:e15-23.
49. Perz JF, Craig AS, Coffey CS, et al. Changes in antibiotic prescribing for children after a community-wide campaign. JAMA2002;287:3103-9.
50. Hennessy TW, Petersen KM, Bruden D, et al. Changes in antibiotic-prescribing practices and carriage of penicillin-resistant Streptococcus pneumoniae: A controlled intervention trial in rural Alaska. Clin Infect Dis 2002;24:1543-50. Epub 2002 May 21.
51. Parrino TA. Controlled trials to improve antibiotic utilization: a systematic review of experience, 1984-2004. Pharmacotherapy 2005;25:289-98.
52. Do Bugs Need Drugs? A community program for wise use of antibiotics. Alberta: Alberta Health and Wellness. Available: www.dobugsneeddrugs.org/ (accessed 2009 Jan. 21).
53. Blondel-Hill E, Fryters S. Bugs and Drugs. Edmonton: Capital Health; 2006.
54. Marra F, Patrick DM, White R, et al. Effect of formulary policy decisions on antimicrobial drug utilization in British Columbia. J Antimicrob Chemother 2005; 55:95-101.